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Abstract 
Marine natural product drug discovery has begun to play an important role in the 
treatment of diseases. Early drug discovery from natural products came primarily from plants, 
but after the discovery and development of penicillin, scientists started looking at natural 
products from microorganisms. Numerous natural products have been discovered from members 
of the order Actinomycetales, particularly in the genus Streptomyces, due to their metabolic 
diversity in the production of biologically active secondary metabolites. Ascidians, also known 
as tunicates, are marine invertebrates that contain many host-associated microbes. Adult 
tunicates are sessile, which makes them vulnerable to predators, and thus, they are hypothesized 
to use host-associated bacteria and their secondary metabolites for chemical defense. Many 
secondary metabolites cannot be produced under laboratory conditions because growth 
conditions in a flask culture differ from conditions of the natural environment. One method, 
mixed fermentation, has been show to increase yields of previously described metabolites, cause 
production of previously undetected metabolites, and increase antibiotic activity of co-cultured 
extracts. A Streptomyces sp. from a Panamanian tunicate was isolated and subsequently co-
cultured with challenge organisms Bacillus subtilis, methicillin-sensitive Staphylococcus aureus 
(MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa 
and extracted. The minimum inhibitory concentration of the extracts and the LC-MS profiles 
show upregulation of the challenge extracts, particularly the Streptomyces sp. co-cultured with 
MRSA. The competitive interactions of co-cultures may enhance metabolite production and 
further our understanding of microbial interactions. 
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Introduction 
 Natural products produced from microbes and microbial interactions have played a 
significant role in drug discovery and the treatment of diseases (Newman and Cragg 2012). 
Almost two-thirds of all small molecule drugs launched from 1981 to 2006 were derived from 
natural products (Pettit 2009). Early drug discovery from natural products focused primarily on 
plants, but after the discovery and development of penicillin, scientists started looking at natural 
products from microorganisms (Cragg and Newman 2013). New antimicrobial drugs need to be 
discovered and developed due to the increasing resistance in pathogenic bacteria (Malapaka et al. 
2007). 
Microbial communities in marine invertebrates have been extensively studied and have 
been shown to contain many bioactive compounds. Ascidians, a type of marine invertebrate, 
have been found to contain various secondary metabolites with pharmaceutical potential (Donia 
et al. 2011). Also known as tunicates, ascidians become sessile when they mature and inhabit 
many different marine environments. Although not closely related to sponges phylogenetically, 
they adopt a similar sedentary, filter-feeding life style (Schmidt and Donia 2010). A common 
trait of marine invertebrates is the symbiotic microbial communities they typically house (Erwin 
et al. 2014). These invertebrates provide nutrients and an environment to inhabit, and the 
structural and functional diversity of these communities provide evidence that the host provides 
fertile microbial niches (Erwin et al. 2014). Being sessile, tunicates are vulnerable to predators 
and thus they are hypothesized to use host-associated bacteria and their secondary metabolites 
for chemical defense. Approximately 1,000 marine natural products have been isolated from 
ascidians (Schmidt and Donia 2010). Many of these secondary metabolites have been shown to 
be important for biotechnology and drug discovery (Erwin et al. 2014).  
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Bacteria within the order Actinomycetales are very abundant in the marine environment 
and have found to been a great source of natural products due to their metabolic diversity in the 
production of biologically active secondary metabolites (Nett et al. 2009). Actinobacteria have 
been found to be well adapted to living in marine invertebrates, such as sponges, corals, and 
ascidians (Valliappan et al. 2014).  In a study that analyzed 203 16S rRNA gene sequences from 
GenBank, approximately 34 genera within 16 families of the order Actinomycetales were 
associated with tunicates (Valliappan et al. 2014). Of all the marine bacteria discovered, 
actinomycetes comprise approximately 10%, but extensive research on actinobacteria has 
resulted in 45% of the 22,000 biologically active compounds obtained from microbes 
(Subramani and Aalbersberg 2013). Actinobacteria continue to be a potential source for 
undiscovered biologically active compounds.  
Actinomycetes are often part of host-associated microbial communities that produce 
secondary metabolites hypothesized to protect the host from the external environment. They 
produce a wide variety of natural products including polyketides, isoprenoids, phenazines, 
peptides, indolocarbazoles, and sterols (Valliappan et al. 2014). Many of these compounds have 
been shown to have antimicrobial, anticancer, antiviral, antiparasitic, antioxidant, anti-HIV, and 
many other biological activities (Manivasagan et al. 2014). Actinomycetes have been discovered 
to dedicate up to 10 percent of their genome to secondary metabolite biosynthesis (Carlson et al. 
2015). Much of the research on actinomycetes has been devoted to the genus Streptomyces, and 
thus, of the secondary metabolites produced by actinomycetes, the majority of the compounds 
isolated have been produced by Streptomyces sp. (Fenical and Jensen 2006). Even so, only 
approximately 3% of the natural product potential of Streptomyces sp. has been discovered, 
thought to be due to the silencing of genes under laboratory conditions (Gontang et al. 2010). 
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Actinomycetes, particularly in the genus Streptomyces, have the genetic capability to produce 
marine natural products, most of which have not been discovered.  
Even with the genetic capacity to produce metabolites, one issue with natural product 
discovery is that bacteria have the ability to produce many secondary metabolites that cannot be 
produced under laboratory conditions because growth conditions in a flask culture differ from 
conditions of the natural environment (Shank and Kolter 2009). Genomic analyses reveal a great 
abundance of biosynthetic gene clusters indicative of the potential to produce secondary 
metabolites, especially in Streptomyces, but only a small portion are expressed under common 
laboratory conditions (Hoshino et al. 2015). 
Microorganisms interact with each other in the natural environment, and these 
interactions are thought to be an ecological driving force for the production of bioactive 
secondary metabolites (Oh et al. 2007). Many marine microorganisms produce these bioactive 
secondary metabolites in response to environmental conditions, such as limited nutrients, space, 
or pathogenic fungi or bacteria. Numerous methods have been used to maximize the chemical 
diversity of bacteria. One method, mixed fermentation, has been show to increase yields of 
previously described metabolites, causing production of previously undetected metabolites, and 
increasing antibiotic activity of co-cultured extracts (Pettit 2009). Competition in co-cultures 
may result in the induction of secondary metabolites that cannot be produced while cultured 
independently (Oh et al. 2005). The competitive interactions in co-cultures may enhance 
metabolite production and thus may further our understanding of microbial interactions. 
Bacterial-bacterial interactions have been shown to induce production of secondary 
metabolites. Table 1 summarizes literature reports of co-culture experiments and the secondary 
metabolites that were produced. In one experiment, 10 mL of Nocardiopsis sp. and 10 mL of 
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Actinokineospora sp. were co-cultured in 1 L of media and incubated for 7 days (Dashti et al. 
2014). Three secondary metabolites were induced in the co-culture that were not detected in the 
monocultures (Dashti et al. 2014).  In another study, Streptomyces sp. cultivated with mycolic 
acid containing bacterium resulted in the isolation of three novel cytotoxic butanolides, 
chojalactones A-C (Hoshino et al. 2015). One mL of each individual culture was added to 100 
mL of broth and cultured for 6 days (Hoshino et al. 2015). Another mixed fermentation 
experiment also used a mycolic acid containing bacterium, Tsukamurella pulmonis, to induce 
secondary metabolite production in a Streptomyces sp. leading to the production of a novel 
antibiotic, alchivemycin A (Onaka et al. 2011). Mycolic acid is thought to localize in the outer 
cell layer of the inducer, influencing secondary metabolite production in the Streptomyces sp. 
(Onaka et al. 2011).  
In another study testing bacterial-bacterial interactions, 95 actinomycete strains were co-
cultured with Proteobacteria, Firmicutes, and Actinobacteria (Carlson et al. 2014). Results 
showed that 65% of Proteobacteria were able to induce the production of the antibiotic 
resistomycin, compared to 5.9% of Firmicutes and 9.1% of Actinobacteria (Carlson et al. 2014). 
This indicates that not all challenge pathogens are able to induce production of secondary 
metabolites. However, these results show that a certain phylum, Proteobacteria, was able to 
induce the production of resistomycin more than others at 65% (Carlson et al. 2014).  
Competition experiments were also conducted to test istamycin production in 
Streptomyces tenjimariensis with competitive species inoculated 24 prior, 24 after, and co-
inoculated (Slattery et al. 2000). Twelve of the 53 species of marine bacteria caused an increase 
in production of istamycins, with significantly higher levels of production when S. tenjimariensis 
was pre-established (Slattery et al. 2000). Twelve of the 53 species tested induced increased 
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production of the istamycins, and there was higher istamycin production when the challenge 
organism was inoculated after S. tenjimariensis was already pre-established (Slattery et al. 2000). 
Fungal-bacteria interactions can also be employed with either the fungus or bacterium 
being the challenge organism. A fungus, Pestaliotia sp. was cultured in 1 L of media and 
challenged with 10 mL of a bacterial strain after 24 hours and incubated for 6 additional days 
(Cueto et al. 2001). This induced the production of a new antibiotic, pestalone, in response to 
bacterial challenge (Cueto et al. 2001). In another bacterial challenge, 1 mL of a 3-day bacterial 
culture was added into 1 L of a 3-day fungal culture and incubated for 2 days (Oh 2005). The 
cytotoxic diterpenoids, libertellenones A-D, were produced by the marine-derived fungus in 
response to challenge with a proteobacterium (Oh et al. 2005). With the same method, a marine 
actinomycete challenge organism induced the production of emericellamides A and B in a 
marine-derived fungus (Oh et al. 2007). 
On the other hand, fungi can be used as challenge organisms against bacterial strains. To 
induce production of secondary metabolites in a mine drainage-derived Sphingomonas bacterial 
strain, 250 μL of a fungus was inoculated into a 2-day culture of the bacterium and incubated for 
15 days (Park et al. 2009). The mixed fermentation resulted in isolation of an antibiotic-
antitumor metabolite, glionitrin A (Park et al. 2009).  
 Fungal-fungal interactions have also been found to cause induction of new secondary 
metabolites. One method employed co-cultures of agar plugs containing mycelial growth in 
liquid media where a new xanthone derivative was isolated from two mangrove fungi (Li et al. 
2011). In another study, a new antibacterial alkaloid, aspergicin, was also produced in mixed 
fermentation of two marine-derived mangrove epiphytic fungi (Zhu et al. 2011).  Using a similar 
co-culture method in another experiment, a novel alkaloid, marinamide, and its methyl ester were 
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produced with co-culture of two endophytic fungi from mangroves in the South China Sea (Zhu 
and Lin 2006). Another method employed agar co-cultures of two fungi for the formation of new 
lipoaminopeptides, acremostatins A, B, and C (Degenkolb et al. 2001). 
Table 1: Co-culture experiments and secondary metabolites in literature. 
 
Bacterial-Bacterial Interactions 
Organism 
Challenge 
Organism 
Method of 
Co-Culture 
New 
Compound(s) 
or Increased 
Production 
Activities of 
Compound Reference 
Actinokineospora 
sp. (B)1 
Nocardiopsis 
sp. (B)1 
10 mL of each 
culture in 1L 
added 
together 
3 new 
compounds2 
Antibiotic 
(Phenazine) 
Dashti et 
al. 2014 
Streptomyces sp. 
(B) 
Mycolic acid 
containing 
bacterium (B) 
1 mL of each 
culture in 100 
mL added 
together 
Chojalactones 
A-C 
Cytotoxic Hoshino et 
al. 2015 
Streptomyces 
lividans (B) 
Tsukamurella 
pulmonis (B) 
3 mL of 
bacteria and 1 
mL of 
challenge 
organism in 
500 mL 
culture 
Alchivemycin 
A 
Antibiotic Onaka et 
al. 2011 
Streptomyces sp. 
(B) 
Four strains of 
Proteobacteria 
(B) 
Co-culture for 
4-14 days 
(volume and 
time 
dependent on 
bacteria used) 
Resistomycin Antibiotic Carlson et 
al. 2014 
Streptomyces 
tenjimariensis (B) 
Marine 
bacteria (B) 
Challenge 
organism 
inoculated 24 
prior, 24 after, 
and at the 
same time 
with equal 
cell 
concentrations 
Istamycin A 
and B 
Antibiotic Slattery et 
al. 2000 
1 Organism is either organism or challenge organism and cannot be determined. 
2 N-(2-hydroxyphenyl)-acetamide, 1,6-dihydroxyphenazine, and 5a,6,11a,12-tetrahydro-5a,11a-
dimethyl[1,4]benzoxazino[3,2-b][1,4]benzoxazine. 
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Table 1 (continued): Co-culture experiments and secondary metabolites in literature. 
 
Bacterial-Fungal Interactions 
Organism 
Challenge 
Organism 
Method of 
Co-Culture 
New 
Compound(s) 
or Increased 
Production 
Activities of 
Compound Reference 
Sphingomonas 
sp. (B)1 
Aspergillus 
funigatus (F)1 
After 2 days, 
250 μL of 
challenge 
added to 500 
mL culture 
Glionitrin A Antibiotic, 
antitumor 
Park et al. 
2009 
Libertella sp. 
(F) 
Marine 
proteobacterium 
(B) 
After 3 days, 
1 mL of 
challenge into 
1 L culture 
Libertellenones 
A-D 
Cytotoxic Oh et al. 
2005 
Emericella sp. 
(F) 
Salinospora 
arenicola (B) 
After 3 days, 
1 mL of 
bacterial 
challenge into 
1 L culture 
Emericellamid
es A and B 
Antibiotic Oh et al. 
2007 
Rosenvingea 
sp. (F) 
Unidentified 
marine 
bacterium 
After 24 
hours, 10 mL 
of bacterial 
challenge into 
1 L culture 
Pestalone Antibiotic, 
cytotoxic 
Cueto et 
al. 2001 
Fungal-Fungal Interactions 
Organism Challenge 
Organism 
Method of 
Co-Culture 
New 
Compound(s) 
or Increased 
Production 
Activities of 
Compound 
Reference 
Mangrove 
fungus (F) 
Mangrove 
fungus (F) 
Co-
inoculation of 
agar plugs 
Xanthone 
derivative 
Antibiotic Li et al. 
2011 
Mangrove 
endophytic 
fungus (F) 
Mangrove 
endophytic 
fungus (F) 
Co-
inoculation 
Marinamide 
and its methyl 
ester 
Antibiotic Zhu and 
Lin 2006 
Mangrove 
endophytic 
fungus (F) 
Mangrove 
endophytic 
fungus (F) 
Co-
inoculation of 
agar plugs 
Aspergicin Antibiotic Zhu et al. 
2011 
Acremonium 
sp. (F)1 
Mycogone 
rosea (F)1 
Surface co-
cultures on 
agar 
Acremostatins 
A, B, and C 
Lipoamino-
peptides 
Degenkolb 
et al. 2001 
1 Organism is either organism or challenge organism and cannot be determined 
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 We have isolated a Panamanian tunicate-associated Streptomyces sp. that has extensive 
secondary metabolite biosynthesis potential, as discovered via whole genome sequencing. The 
bacterial extract also shows potent antimicrobial activity against several human pathogens. We 
hypothesize that challenging this strain with human pathogens, such as Bacillus subtilis (BS), 
methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus 
aureus (MRSA), and Pseudomonas aeruginosa (PA), may increase production of antimicrobial 
compounds and thus increase activity against the pathogens. Co-cultures with small quantities of 
challenge organisms with cultures of this Streptomyces sp. will be performed and extracts will be 
tested against the challenge pathogens to determine the minimum inhibitory concentration 
(MIC). We will also analyze the extracts for increased production of compounds or novel 
compounds.  
 
Experimental 
General Experimental 
Liquid chromatography mass spectrometry data was collected on an Agilent ESI single 
quadrupole mass spectrometer coupled to an Agilent high performance liquid chromatography 
(HPLC) system with a G1311 quaternary pump, G1322 degasser, and a G1315 diode array 
detector using an Eclipse XDB-C18 (4.6 × 150 mm, 5 μm) RP-HPLC column with a solvent 
gradient of 25-100% acetonitrile (ACN) with 0.1% formic acid over 75 minutes. All dry media 
and agar for culturing were purchased from Difco and subsequently prepared with water and 
autoclaved. All reagents and HPLC grade solvents were purchased from Sigma Aldrich. All 
bacterial products were purchased from ATCC.  
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Tunicate Collection and Bacterial Isolation 
The tunicate, Styela canopus, was collected in a mangrove from Bastimentos Park in 
Bocas de Toro, Panama (9°17.398’ N 82°11.106’ W). The tunicate was rinsed with ethanol then 
sterile seawater, homogenized, and plated onto a Reasoner’s 2A (R2A) plus instant ocean (IO) 
agar plate with cycloheximide (80 mgl-1) and nalidixic acid (20 mgl-1) to reduce fungal 
contamination and fast growing bacteria. The R2A medium contained yeast extract 0.5g, 
proteose peptone no. 3 0.5g, casamino acids 0.5g, dextrose 0.5g, soluble starch 0.5g, sodium 
pyruvate 0.3g, dipotassium phosphate 0.3g, and magnesium sulfate 0.05g in 1 liter of Millipore 
water (Becton, Dickinson and Company, New Jersey, USA). PTY087I2 was isolated onto R2A + 
IO agar and stored on nutrient agar slants. The bacterium was re-streaked onto yeast starch 
peptone, YSP +IO agar, a nutrient rich agar. This medium contained soluble starch 5g, trypticase 
peptone 1g, yeast extract 2g in 1 liter of Millipore water (Becton, Dickinson and Company, New 
Jersey, USA). The bacterium was stored in liquid nitrogen and -80 C cryogenic vials.  
Co-Culture in Liquid Media and Extraction 
A confluent culture of PTY087I2 was prepared prior to the start of the experiment. In 
addition, the challenge pathogens were streaked out onto agar plates. On day one, 1 mL of 
culture was added to 25 mL of YSP+IO broth in a 125 mL baffled flask to the monoculture and 
each co-culture (Derewacz et al. 2015). One colony of each pathogen was inoculated into 5 mL 
of YSP+IO broth. On day two, 200 μL of each challenge pathogen was added to the respective 
co-culture and challenge pathogen monoculture. The cultures were incubated at 30 oC at 200 
RPM for 6 days after challenging. After confluent growth in the large culture, HP20 Diaion 
beads were prepared by washing them in a frit filter with methanol and water. The beads were 
then added to the culture and placed on a shaker for 24 hours. The purpose of the beads was to 
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temporarily attach to secondary metabolites produced by the bacteria. The beads were first 
washed with 60 mL of deionized water. The metabolites were then released from the beads using 
organic solvents. The beads were washed with 60 mL of methanol (MeOH), 60 mL of 
dichloromethane (DCM), and 60 mL of acetone. All organic solvents were combined and dried 
in vacuo.  
96 Well Bioassays 
 All bioassays used 96 well plates flat bottom plates from CostarTM. Extracts were 
prepared at stock concentrations of 50 mg/mL. The 96 well bioassays were modified from Zgoda 
and Porter 2011. Pathogens were inoculated into 5 mL of broth at an optical density (OD) of 
0.08-0.10 equivalent to 0.5 McFarland Standard (approximately 1 x 108 CFU/mL). To prepare 
the master mix, 1.6 mL of the inoculum were added, along with 7.84 mL of sterile water, and 6.4 
mL of broth into a 50 mL falcon tube. With a multi-channel pipette, 198 μL of master mix was 
aliquoted into the designated wells except the sterility and media wells. 98 μL of sterile water 
and 100 μL of broth was added into the sterility control wells. 2 μL of dimethyl sulfoxide 
(DMSO) was added to the sterility and negative controls, 2 μL of antibiotic (X, Y, or Z) was 
added to positive controls, and 2 μL of extract was added to sample wells. All of the controls and 
samples were tested in triplicate for a minimum of two times. The outer wells were filled with 
sterile broth. The plates were read at 0 and 24 hours at 600 nm in a plate reader using a Synergy 
H1 Hybrid Reader from Biotek. All wells were compared with the DMSO negative control. 
Whole Genome Sequencing 
PTY087I2 was inoculated into YSP+IO media and incubated at 30 oC for a confluent culture. 
DNA was extracted from 1 mL of confluent culture using the Promega Wizard Genomic DNA 
Purification Kit according to manufacturer’s protocol (Promega Corporation, Wisconsin, USA). 
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Subsequently, 200 ng of DNA was used with Truseq. The phylogenetic tree was constructed 
using ORFcor pipeline (Klassen and Currie 2013), fasttree and iTol.  
Antibiotics and Secondary Metabolite Analysis Shell (AntiSMASH) Genome 
 The genome was analyzed using anti-SMASH 3.0.5 for identification of secondary 
metabolite clusters and percent similarity (Weber et al. 2015). 
Results and Discussion 
 The Panamanian actinomycete (PTY087I2) was originally isolated from an R2A+IO agar 
plate. Upon reisolation onto a nutrient rich YSP+IO agar plate, we noticed that the bacterium 
was powdery white and turned the agar blue (Figure 1). PTY087I2 was cultured in liquid 
YSP+IO media and extracted (Figure 1). The extract showed strong inhibition against MRSA 
and Bacillus subtilis (Table 4), and thus was chosen as the bacterium of interest for co-culture 
challenge experiments.  
The bacterium resembled an actinomycete based on the white powdery spores. The DNA 
of the bacterium was extracted and sequenced to determine the genus and species. After the 
whole genome was sequenced, the bacterium was found to be a Streptomyces sp., which was 
94.67% identical to a known species, Streptomyces griseus accession number ADFC00000000. 
In addition, antiSMASH analysis shows several gene clusters in PTY087I2 that were similar to 
known gene clusters (Table 2). The genome was shown to contain 2 bacteriocin, 8 NRPS, 2 
NRPS-T1PKS, 1 otherKS-NRPS, 4 terpene, 3 lantipeptide, 1 melanin, 2 T3PKS, 2 ectoine, 2 
siderophone, 1 T2PKS, 1 butyrolactone, 1 otherKS-T1PKS, 1 thiopeptide-lantipeptide, 2 
lassopeptide, 1 lantipeptide-melanin, 1 T1PKS-NRPS, 1 ladderane-arylpolyene, and 1 other 
cluster. Of those clusters, 30 of them were similar to known clusters with 7 clusters having 100% 
similarity for SGR PTMs, melanin, ectoine, griseobactin, SRO15-2005 (lassopeptide), SRO15-
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2005 (NRPS), and amfS biosynthesis (Table 2). The antiSMASH analysis shows that the 
Streptomyces sp. has great potential to produce a variety of antibiotic secondary metabolites.  
After co-cultures and extraction, extracts were analyzed via LC-MS. The UV 
chromatograms of each challenge culture extract were overlayed with the UV chromatogram of 
the monoculture (Figure 2A-D). The peaks of interest were determined to elute at 5, 10, 11, 13, 
16, 34, and 68 minutes and labeled A-G (Figure 3). The peaks heights for all challenge extract 
peaks appear higher than the peaks of PTY monoculture. The areas under the peaks were 
measured via integration (Table 3). All the areas of the peaks were significantly higher in the 
challenge extracts as compared with monoculture extracts for peaks B, C, D, and E. For peaks F 
and G, PTY+BS, PTY+MSSA, and PTY+MRSA had significantly higher areas. For the highest 
peak, A, at 5 minutes PTY+BS and PTY+MSSA had higher area under the peak than PTY. 
Interestingly, most of the areas under the peaks for the challenge extracts were higher than the 
mono-culture extract with the exception of peak A of PTY+PA.  
 
Figure 1: PTY087I2 on YSP+IO agar plate (left) and in YSP+IO liquid media (right). 
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Table 2: antiSMASH genome of PTY087I2 with most similar known gene clusters and percent 
similarities. 
 
Most Similar Known Cluster Percent Similarity Molecular Weights (g/mol) 
SGR PTMs 100  
Melanin 100 318.283 
Ectoine 100 142.156 
Griseobactin 100  
SRO15-2005 (Lassopeptide) 100  
SRO15-2005 (Nrps) 100  
AmfS 100  
Granaticin 83 444.388 
Desferrioxamine B 80 560.684 
Coelibactin 72  
Coelichelin 72 565.58 
Hopene 69 410.718 
Nataxazole 59  
Labyrinthopeptin A1, A2, A3 40  
Skyllamycin (Ladderane-Arylpolyene) 26  
Skyllamycin (other) 26  
Pristinamycin 23 
IA 866.96 
IB 852.93 
IIA 525.59 
IIB 527.62 
Kinamycin 22 484.499 
Steffimycin 19 
574.532 
B 588.557 
Calcium-dependent antibiotic 15  
Enduracidin 10 
A 2355.61 
B 2369.329 
Skyllamycin (Nrps) 10  
Herboxidiene (Nrps) 9 438.597 
Herboxidiene (T3pks) 8 438.597 
Guadinomine 7 
A 518.281 
B 502.565 
D 544.297 
Oxazolomycin 6 655.778 
Herboxidiene (T3pks) 6 438.597 
Daptomycin 4 1620.67 
Tetronasin 3 602.798 
Phosphonoglycans 3  
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Figure 2: LC-MS UV chromatogram overlay of challenge culture against monoculture. A: PTY 
(red) and PTY+BS (blue). B: PTY (red) and PTY+MSSA (blue). C: PTY (red) and PTY+MRSA 
(blue). D: PTY (red) and PTY+PA (blue). 
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Figure 2 continued: LC-MS UV chromatogram overlay of challenge culture against monoculture. 
A: PTY (red) and PTY+BS (blue). B: PTY (red) and PTY+MSSA (blue). C: PTY (red) and 
PTY+MRSA (blue). D: PTY (red) and PTY+PA (blue). 
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Figure 3: LC-MS UV chromatogram overlay of all extracts showing peaks of interest A-G. PTY 
(blue), PTY+BS (green), PTY+MSSA (red), PTY+MRSA (pink), PTY+PA (brown). 
 
 
Table 3: Area of peaks of interest in UV chromatogram of co-culture and monoculture extracts. 
Area of Integrated Peaks of Interest on LCMS Chromatogram 
Peak 
Extract 
A 
(5 mins) 
B 
(10 mins) 
C 
(11 mins) 
D 
(13 mins) 
E 
(16 mins) 
F 
(34 mins) 
G 
(68 mins) 
PTY 930.4 231.3 15.1 13.2 5.4 27.3 29 
PTY+BS 2117.8 826.0 208.4 149.7 58.7 86.6 110.7 
PTY+MSSA 1480.5 1107.4 83.6 25.9 38.2 84.2 81.9 
PTY+MRSA 962.2 463.2 349.3 206.2 139.6 56.4 67.1 
PTY+PA 739.0 335.1 87.4 49.7 39.3 33.3 33.8 
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The fold increase for the peak areas of the co-cultures compared to the monoculture was 
also calculated (Figure 4). The figure shows the most substantial fold increases in peaks C-E, 
particularly in the PTY+MRSA extract. The peaks C, D, and E in the PTY+MRSA extract 
showed a 23.1, 15.6, and 25.9-fold increase in area, respectively. The peaks for PTY+BS, 
PTY+MSSA, and PTY+PA also showed moderate fold increases, as compared to the 
monoculture. The challenge pathogens were able to induce an increase production of compounds 
that are potentially antibacterial at the peaks of interest A-G.  
 
Figure 4: Fold increase of area under integrated peaks of interest, A-G, from Table 3 above of 
the co-culture extracts against the monoculture extract. 
 Positive ion mass spectrometry data was obtained for peaks C-E to determine the 
molecular weights of compounds C, D, and E (retention times 11, 13, and 16 minutes, 
respectively). Peak C has a [M+H]+ of 447.2, peak D has a M+H of 445.2, and peak E has a 
M+H of 447.1. Based on the molecular weights of the known compounds found in the 
Streptomyces sp. genome, the mass spectrometry data for peak D matched with granaticin (Table 
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granaticin is 444.388, matching the mass spectrometry of peak D (Figure 5). The extracted ion 
chromatogram (EIC) for the molecular weight of granaticin shows the peaks that match with that 
particular molecular weight (Figure 6). The extracted ion in positive mode shows that peaks A, 
B, and D match with the molecular weight with peak D having the highest abundance (Figure 6). 
The extracted ion in negative mode shows that only peak D contains a compound with that 
molecular weight (Figure 6). The EIC results confirm the mass spectrometry data of the potential 
presence of granaticin in peak D. Granaticin is an antibiotic that was originally isolated from 
Streptomyces olivaceus and produced by many other actinomycetes (Snipes et al. 1979). It has 
shown to have antibiotic activity against Gram-positive bacteria but have little or no activity 
against Gram-negative bacteria. 
 Furthermore, the mass spectrometry of peaks C and E showed similar molecular weights 
to granaticin, which could indicate a possible derivative of granaticin. A derivative of granaticin 
that could potential have a [M+H]+ of 447 g/mol is granatomycin D with a molecular weight of 
446.4041 g/mol. The EIC for the molecular weight of granatomycin D with a range of ±0.1 
g/mol shows that there are peaks that match with the molecular weight (Figure 7). The extracted 
ion in positive mode shows that peaks C and E match with the molecular weight with both peaks 
having high abundance (Figure 7). The extracted ion in negative mode shows that only peak C 
contains a compound with the molecular weight of granatomycin D (Figure 7). The EIC results 
confirm the mass spectrometry data of the potential presence of granatomycin D in peak C (both 
positive and negative ion mode) and peak E (positive ion mode only). Granatomycin has similar 
physicochemical properties of granaticin and has shown to have antibiotic activity against Gram-
positive and Gram-negative bacteria (Fleck et al. 1980). 
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Figure 5: Positive ion mass spectrometry of peaks C-E in PTY+MRSA chromatogram. 
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Figure 6: Extracted ion chromatogram (EIC) of granaticin molecular weight (444.3882 g/mol) in 
negative ion (top) and positive ion (bottom) mode for PTY+MRSA sample. 
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Figure 7: Extracted ion chromatogram (EIC) of granatomycin D molecular weight (446.4041 
g/mol) in negative ion (top) and positive ion (bottom) mode for PTY+MRSA sample. 
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 The extracts were all tested against the challenge pathogens in 96 well bioassays. Table 4 
and Figures 8-11 summarize MIC values of the challenge extracts against BS, MSSA, MRSA, 
and PA. None of the extracts showed activity against Pseudomonas aeruginosa (MIC > 400 
μg/mL). All of the extracts showed strong activity against Bacillus subtilis (MIC = 3.125 μg/mL 
for PTY+MRSA and MIC = 6.25 μg/mL for the other four extracts). PTY+MSSA and PTY 
showed the same activity against MSSA and MRSA, MIC = 50 μg/mL. PTY+BS, PTY+PA, and 
PTY+MRSA showed increased activity against MRSA and MSSA with lower MIC values 
(Table 4). PTY challenged with MRSA had the highest activity against both MSSA and MRSA. 
Figure 6 displays the different concentrations of challenge extracts tested against MRSA. The 
percent control activity (PCA) is set against the negative control (1% DMSO). The MIC was 
determined from the lowest concentration at which the PCA value was less than 0, which means 
that there was inhibition (no growth) of MRSA in the wells. PTY+MRSA had the lowest MIC 
value of 6.25 μg/mL versus the PTY monoculture of 50 μg/mL. PTY+MRSA also had a lower 
MIC value of 3.125 μg/mL compared to the other co-cultures and monocultures. This suggests 
that MRSA was able to challenge the Streptomyces sp. and increase production of the 
antibacterial compound.  
Table 4: MIC values from 96 well bioassays for PTY087I2 challenge extracts against challenge 
pathogens. 
Minimum Inhibitory Concentration of Challenge Extracts Against Pathogens (μg/mL) 
Pathogen 
Extract 
Bacillus subtilis MSSA MRSA Pseudomonas 
aeruginosa 
PTY 6.25 50 50 >400 
PTY+BS 6.25 25 25 >400 
PTY+MSSA 6.25 50 50 >400 
PTY+MRSA 3.125 6.25 6.25/12.5 >400 
PTY+PA 6.25 12.5 12.5 >400 
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Figure 8: 96 well bioassay of PTY087I2 challenge extracts against MRSA at different 
concentrations (μg/mL).  
 
Figure 9: 96 well bioassay of PTY087I2 challenge extracts against MSSA at different 
concentrations (μg/mL).  
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Figure 10: 96 well bioassay of PTY087I2 challenge extracts against Pseudomonas aeruginosa at 
different concentrations (μg/mL).  
 
Figure 11: 96 well bioassay of PTY087I2 challenge extracts against Bacillus subtilis at different 
concentrations (μg/mL).  
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 The challenge extracts run through LC-MS exhibited an upregulation of compounds at 
several peaks of the chromatogram (Figure 3). In antibacterial assays, these same challenge 
extracts also showed more activity against MRSA, MSSA and Bacillus subtilis, particularly the 
PTY+MRSA co-culture challenge extract (Table 4).  PTY+MRSA showed the greatest activity 
as well as the greatest fold increase on LC-MS. Upon further analysis of the mass spectrometry 
EIC, this Streptomyces sp. likely produces the antibiotic granaticin in peak D that has 
antibacterial activity against Gram-positive bacteria but not Gram-negative bacteria (Figure 6). 
In our results, the extracts show activity against the Gram-positive bacteria, MRSA, MSSA, and 
Bacillus subtilis and no activity against the Gram-negative bacterium, Pseudomonas aeruginosa 
(Table 4). Peaks C and E also have likely contain a derivative of granaticin, granatomycin D. 
The peaks that potentially contain the antibiotics were upregulated in the co-cultures and the 
upregulation of the production of the compounds were confirmed via antibacterial assays. 
Conclusions 
The MIC values and LC-MS peaks were indicative of an increase in activity and an 
increase of production of antibacterial compounds. The antiSMASH analysis and mass 
spectrometry data showed the possibility of the production of granaticin and granatomycin in 
peaks C-E. Our results suggest that MRSA induced increased production of antibacterial 
compounds active against MRSA, MSSA and Bacillus subtilis as compared with the 
Streptomyces sp. monoculture. These results indicate that co-culturing with human pathogens 
can be used as a method to increase yield of antibiotic compounds under laboratory conditions. 
Co-cultures with small amounts of challenge pathogens may provide an environmental stress that 
promotes increased biosynthesis of the active antibacterial compounds. 
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Further co-culture experiments should also be conducted to determine the effect of 
adding varying amounts of the challenge pathogen. Other future research experiments include 
optimum timing of challenge pathogen inoculation and optimal growth and culturing conditions. 
Future direction will also include fractionation and isolation of active compounds against 
MRSA, MSSA, and Bacillus subtilis.   
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